JP2023518409A5 - - Google Patents
Info
- Publication number
- JP2023518409A5 JP2023518409A5 JP2022556016A JP2022556016A JP2023518409A5 JP 2023518409 A5 JP2023518409 A5 JP 2023518409A5 JP 2022556016 A JP2022556016 A JP 2022556016A JP 2022556016 A JP2022556016 A JP 2022556016A JP 2023518409 A5 JP2023518409 A5 JP 2023518409A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- angptl3
- modified
- galnac
- phosphorothioate bond
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023203827A JP7749645B2 (ja) | 2020-03-18 | 2023-12-01 | Ａｎｇｐｔｌ３発現を阻害する組成物及び方法 |
| JP2025157843A JP2026016378A (ja) | 2020-03-18 | 2025-09-24 | Ａｎｇｐｔｌ３発現を阻害する組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062991335P | 2020-03-18 | 2020-03-18 | |
| US62/991,335 | 2020-03-18 | ||
| PCT/US2021/022967 WO2021188795A1 (en) | 2020-03-18 | 2021-03-18 | Compositions and methods for inhibiting angptl3 expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023203827A Division JP7749645B2 (ja) | 2020-03-18 | 2023-12-01 | Ａｎｇｐｔｌ３発現を阻害する組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518409A JP2023518409A (ja) | 2023-05-01 |
| JP2023518409A5 true JP2023518409A5 (enExample) | 2023-09-15 |
| JP7398007B2 JP7398007B2 (ja) | 2023-12-13 |
Family
ID=75478225
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556016A Active JP7398007B2 (ja) | 2020-03-18 | 2021-03-18 | Ａｎｇｐｔｌ３発現を阻害する組成物及び方法 |
| JP2023203827A Active JP7749645B2 (ja) | 2020-03-18 | 2023-12-01 | Ａｎｇｐｔｌ３発現を阻害する組成物及び方法 |
| JP2025157843A Pending JP2026016378A (ja) | 2020-03-18 | 2025-09-24 | Ａｎｇｐｔｌ３発現を阻害する組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023203827A Active JP7749645B2 (ja) | 2020-03-18 | 2023-12-01 | Ａｎｇｐｔｌ３発現を阻害する組成物及び方法 |
| JP2025157843A Pending JP2026016378A (ja) | 2020-03-18 | 2025-09-24 | Ａｎｇｐｔｌ３発現を阻害する組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230287425A1 (enExample) |
| EP (1) | EP4121536A1 (enExample) |
| JP (3) | JP7398007B2 (enExample) |
| KR (1) | KR20220156880A (enExample) |
| CN (1) | CN116096889A (enExample) |
| AU (2) | AU2021236674B2 (enExample) |
| BR (1) | BR112022018667A2 (enExample) |
| CA (1) | CA3172117A1 (enExample) |
| CL (1) | CL2022002521A1 (enExample) |
| IL (1) | IL296549A (enExample) |
| MX (1) | MX2022011550A (enExample) |
| TW (2) | TW202530410A (enExample) |
| WO (1) | WO2021188795A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017021053A2 (en) | 2015-04-13 | 2018-08-14 | Alnylam Pharmaceuticals, Inc. | angiopoietin type 3 (angpt13) irna compositions and methods of use thereof |
| CA3172117A1 (en) * | 2020-03-18 | 2021-09-23 | Bob D. Brown | Compositions and methods for inhibiting angptl3 expression |
| US20230383294A1 (en) * | 2020-10-16 | 2023-11-30 | Sanofi | Novel rna compositions and methods for inhibiting angptl3 |
| BR112023017737A2 (pt) | 2021-03-04 | 2023-10-03 | Alnylam Pharmaceuticals Inc | Composições de irna de angiopoietina-semelhantes 3 (angptl3) e métodos de uso das mesmas |
| WO2023045994A1 (en) * | 2021-09-23 | 2023-03-30 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of angiopoietin-like 3 (angptl3) protein |
| WO2023092102A1 (en) * | 2021-11-19 | 2023-05-25 | Sanegene Bio Usa Inc. | Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereof |
| EP4453210A1 (en) * | 2021-12-22 | 2024-10-30 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors |
| JP2025512445A (ja) * | 2022-04-15 | 2025-04-17 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ｓｃａｐ活性を調節するための組成物及び方法 |
| JP7812495B2 (ja) | 2022-11-23 | 2026-02-09 | イーライ リリー アンド カンパニー | ４’－ホスフェート類似体ヌクレオチドホスホラミダイトを合成する方法 |
| EP4622982A1 (en) | 2022-11-23 | 2025-10-01 | Eli Lilly and Company | Methods of synthesizing a targeting ligand-conjugated nucleotide phosphoramidite |
| EP4638744A1 (en) | 2022-12-22 | 2025-10-29 | Eli Lilly and Company | Oligonucleotide fragments and methods of making rnai agents using the same |
| WO2024151772A2 (en) * | 2023-01-11 | 2024-07-18 | Sirius Therapeutics, Inc. | Polynucleic acid molecules for inhibiting expression of angptl3, pharmaceutical compositions, and uses thereof |
| WO2024175550A1 (en) * | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| CN118599845A (zh) * | 2023-06-27 | 2024-09-06 | 施能康医药科技(苏州)有限公司 | 靶向人血管生成素样蛋白3的核酸及其用途 |
| WO2025096970A2 (en) * | 2023-11-03 | 2025-05-08 | Basecure Therapeutics Llc | Modified oligonucleotides and methods of use thereof |
| TW202539699A (zh) | 2023-12-08 | 2025-10-16 | 美商美國禮來大藥廠 | 含有治療性寡核苷酸之醫藥組合物及使用其之給藥方案 |
| WO2025169133A1 (en) | 2024-02-09 | 2025-08-14 | Astrazeneca Ab | Double-stranded rnai agents and compositions for reducing expression of angiopoietin-like 3 (angptl3) and methods of use thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5804683A (en) | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
| US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| EP1253199A1 (en) | 1993-09-02 | 2002-10-30 | Ribozyme Pharmaceuticals, Inc. | Abasic moieties containing enzymatic nucleic acids |
| US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| WO2003040395A2 (en) | 2001-11-07 | 2003-05-15 | Applera Corporation | Universal nucleotides for nucleic acid analysis |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| WO2010033225A2 (en) | 2008-09-22 | 2010-03-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications |
| WO2010039543A2 (en) | 2008-09-23 | 2010-04-08 | Traversa Therapeutics, Inc. | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
| KR20110110776A (ko) | 2008-12-18 | 2011-10-07 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| WO2011085271A2 (en) * | 2010-01-08 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| CA2839573A1 (en) * | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| AU2012328680A1 (en) | 2011-10-25 | 2014-05-01 | Ionis Pharmaceuticals, Inc. | Antisense modulation of GCCR expression |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| PL3087183T3 (pl) * | 2013-12-24 | 2021-01-11 | Ionis Pharmaceuticals, Inc. | Modulacja ekspresji białka angiopoetynopodobnego 3 |
| WO2015168589A2 (en) * | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
| CN107109405A (zh) | 2014-06-06 | 2017-08-29 | 索尔斯蒂斯生物有限公司 | 具有生物可逆性和非生物可逆性基团的多核苷酸构建体 |
| EP3865576A1 (en) | 2014-12-15 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | Ligand-modified double-stranded nucleic acids |
| EP3929293A3 (en) * | 2015-04-03 | 2022-03-16 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| BR112017021053A2 (en) * | 2015-04-13 | 2018-08-14 | Alnylam Pharmaceuticals, Inc. | angiopoietin type 3 (angpt13) irna compositions and methods of use thereof |
| MD3448426T2 (ro) * | 2016-04-28 | 2025-09-30 | Regeneron Pharma | Metode de tratament al pacienților cu hipercolesterolemie familială |
| WO2018045317A1 (en) | 2016-09-02 | 2018-03-08 | Dicerna Pharmaceuticals, Inc. | 4'-phosphate analogs and oligonucleotides comprising the same |
| AU2018224387B2 (en) * | 2017-02-22 | 2024-08-08 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
| MX2020001912A (es) * | 2017-09-14 | 2020-03-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso. |
| CN112368381A (zh) * | 2018-04-18 | 2021-02-12 | 迪克纳制药公司 | 用于治疗高胆固醇血症和相关病况的pcsk9靶向寡核苷酸 |
| CA3172117A1 (en) * | 2020-03-18 | 2021-09-23 | Bob D. Brown | Compositions and methods for inhibiting angptl3 expression |
-
2021
- 2021-03-18 CA CA3172117A patent/CA3172117A1/en active Pending
- 2021-03-18 KR KR1020227036162A patent/KR20220156880A/ko active Pending
- 2021-03-18 TW TW113148812A patent/TW202530410A/zh unknown
- 2021-03-18 WO PCT/US2021/022967 patent/WO2021188795A1/en not_active Ceased
- 2021-03-18 CN CN202180036489.6A patent/CN116096889A/zh active Pending
- 2021-03-18 BR BR112022018667A patent/BR112022018667A2/pt unknown
- 2021-03-18 JP JP2022556016A patent/JP7398007B2/ja active Active
- 2021-03-18 US US17/906,532 patent/US20230287425A1/en active Pending
- 2021-03-18 MX MX2022011550A patent/MX2022011550A/es unknown
- 2021-03-18 AU AU2021236674A patent/AU2021236674B2/en active Active
- 2021-03-18 TW TW110109858A patent/TWI870563B/zh active
- 2021-03-18 IL IL296549A patent/IL296549A/en unknown
- 2021-03-18 EP EP21718336.7A patent/EP4121536A1/en active Pending
-
2022
- 2022-09-15 CL CL2022002521A patent/CL2022002521A1/es unknown
-
2023
- 2023-12-01 JP JP2023203827A patent/JP7749645B2/ja active Active
-
2025
- 2025-05-22 AU AU2025203784A patent/AU2025203784A1/en active Pending
- 2025-09-24 JP JP2025157843A patent/JP2026016378A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023536974A5 (enExample) | ||
| JP2023103244A5 (enExample) | ||
| JP7442574B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| JP7398007B2 (ja) | Ａｎｇｐｔｌ３発現を阻害する組成物及び方法 | |
| JP2021518125A5 (enExample) | ||
| JP2024514880A5 (enExample) | ||
| JP2024535888A5 (enExample) | ||
| JP2022501040A5 (enExample) | ||
| CN117701562A (zh) | 用于抑制血管生成素-样3(ANGPTL3)的表达的RNAi剂和组合物以及使用方法 | |
| TWI881004B (zh) | 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合 | |
| JP2020529197A5 (enExample) | ||
| JP2024508896A5 (enExample) | ||
| JP2023538284A5 (enExample) | ||
| JP2024516356A5 (enExample) | ||
| CN121057819A (zh) | 双重沉默 | |
| JP2023539341A5 (enExample) | ||
| JP2024516356A (ja) | ケトヘキソキナーゼ（ｋｈｋ）を阻害するための組成物及び方法 | |
| WO2023134705A1 (zh) | 抑制angptl3表达的rna干扰剂及其用途 | |
| JP2024528503A5 (enExample) | ||
| KR20240101580A (ko) | Hbv 치료를 위한 약학 조합물 | |
| JP2024528701A5 (enExample) | ||
| JP2024543195A5 (enExample) | ||
| JP2023526328A5 (enExample) | ||
| US20040220131A1 (en) | Method for treatment of cancerous angiogenic disorders | |
| EP1616009A2 (en) | Method for treatment of angiogenic disorders |